GleamWall
中文EN

VTGN Vistagen Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1411685 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY230.4%
TTM net income YoY5.3%
TTM EPS YoY29.7%
Revenue 3-yr CAGR43.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,541.9%
Net margin-2,474.5%
FCF margin—
EBITDA margin-2,533.2%

Returns

ROE-144.9%
ROA-113.0%
ROIC (approx.)-1,250.0%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.64x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio3.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue$1.27M$486,000
R&D expense$54.97M$39.38M
SG&A expense$18.42M$17.08M
Operating income-$72.13M-$55.97M
Pretax income-$69.68M-$51.41M
Income tax$7,000$7,000
Net income-$69.69M-$51.42M
EBITDA-$71.93M-$55.82M
EPS (basic)-1.83-1.67
EPS (diluted)-1.83-1.67
Weighted avg. shares (diluted)38.07M30.88M
Balance sheet
Cash & equivalents$30.79M$67.13M
Short-term investments$14.61M$13.35M
Current assets$46.94M$82.08M
PP&E, net$427,000$476,000
Total assets$48.56M$84.34M
Current liabilities$12.79M$12.61M
Total liabilities$13.04M$13.95M
Shareholders' equity$35.52M$70.39M
Cash flow statement
Operating cash flow-$66.44M-$42.10M
Investing cash flow-$877,000-$13.15M
Financing cash flow$30.97M$3.21M
Depreciation & amortization$199,000$150,000
Stock-based compensation$4.00M$4.32M

Free plan shows the latest 2 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.